Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion ...

ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, ...

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- (ASX: TLX, Nasdaq: TLX, Telix, the Company) today ...

Telix Pharmaceuticals Limited has entered into an asset purchase agreement with antibody engineering company ImaginAb Inc. to ...

Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.

In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Immunocore Holdings (IMCR – Research Report), with a price ...

With these agreements, the respective parties will work to advance therapeutic candidates for treating fibrotic diseases, osteoarthritis, and Alzheimer’s disease.

Company to present pipeline update at 43rd Annual J.P ... M.D., Ph.D., Senior Vice President, Therapeutic Area Head, Oncology. "We are encouraged by the building momentum in our oncology portfolio ...

Nimbus plans to initiate the first clinical trial of NDI-219216 in the first half of 2025 under the leadership of Anita Scheuber, M.D., Ph.D., Senior Vice President, Therapeutic Area Head ...